Your browser doesn't support javascript.
loading
Association between baseline body mass index and survival in men with metastatic hormone-sensitive prostate cancer: ECOG-ACRIN CHAARTED E3805.
Morgans, Alicia K; Chen, Yu-Hui; Jarrard, David F; Carducci, Michael; Liu, Glenn; Eisenberger, Mario; Plimack, Elizabeth R; Bryce, Alan; Garcia, Jorge A; Dreicer, Robert; Vogelzang, Nicholas J; Picus, Joel; Shevrin, Daniel; Hussain, Maha; DiPaola, Robert S; Cella, David; Sweeney, Christopher J.
Afiliación
  • Morgans AK; Department of Medicine (Hematology and Oncology), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
  • Chen YH; Department of Biostatistics and Computational Biology ECOG-ACRIN Cancer Research Group, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Jarrard DF; Departments of Urology and Medicine, UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Carducci M; Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Liu G; Departments of Urology and Medicine, UW Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
  • Eisenberger M; Department of Oncology, Johns Hopkins University, Baltimore, Maryland, USA.
  • Plimack ER; Department of Hematology and Oncology, Fox Chase Cancer Center, Temple University Health System, Philadelphia, Pennsylvania, USA.
  • Bryce A; Division of Hematology and Medical Oncology, Mayo Clinic, Scottsdale, Arizona, USA.
  • Garcia JA; Department of Medicine, Case Comprehensive Cancer Center, Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, Ohio, USA.
  • Dreicer R; Division of Hematology and Oncology, University of Virginia Cancer Center, Charlottesville, Virginia, USA.
  • Vogelzang NJ; Nevada Cancer Research Foundation, Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, USA.
  • Picus J; Division of Medical Oncology, Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri, USA.
  • Shevrin D; General Oncology, NorthShore University HealthSystem, Evanston, Illinois, USA.
  • Hussain M; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, USA.
  • DiPaola RS; Department of Medicine (Hematology and Oncology), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
  • Cella D; College of Medicine, University of Kentucky College of Medicine, Lexington, Kentucky, USA.
  • Sweeney CJ; Department of Medicine (Hematology and Oncology), Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois, USA.
Prostate ; 82(12): 1176-1185, 2022 09.
Article en En | MEDLINE | ID: mdl-35538398
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Metformina Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Prostate Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Metformina Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies / Risk_factors_studies Límite: Humans / Male Idioma: En Revista: Prostate Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos